

Contents

Chapter 1	Driving Successful Commercial Product Launches.....	1
	<i>Updated by Michael Reiner, MBA</i>	
Chapter 2	Development and Implementation of Regulatory Strategies for Medical Devices... 15	
	<i>Updated by Thomas R. Hutchinson, MS, RAC, FRAPS</i>	
Chapter 3	Core Development Teams.....	21
	<i>Updated by Pamela J. Weagraff, MBA</i>	
Chapter 4	Components of Regulatory Strategy—The Basics	47
	<i>Updated by Melissa Walker, MS, RAC, FRAPS</i>	
Chapter 5	Setting up a Quality Management System	59
	<i>Updated by Abhishek Harde, PMP, RAC</i>	
Chapter 6	Risk Management Strategies for Device Design and Development Processes.....	93
	<i>Updated by Thomas McNamara, MSE, RAC</i>	
Chapter 7	Global Medical Device Labeling Strategies	111
	<i>Updated by Cathleen O’Connell, RPh, PhD</i>	
Chapter 8	Manufacturing	127
	<i>Updated by Andrea Armando, RAC</i>	
Chapter 9	Nonclinical Laboratory Testing	135
	<i>Updated by Dorota Grabowska, PhD and Peter A. Takes, PhD, RAC, FRAPS</i>	
Chapter 10	Global Medical Device Clinical Strategy	149
	<i>Updated by Dawn Norman, MS</i>	
Chapter 11	In Vitro Diagnostic Medical Devices	157
	<i>Updated by Jocelyn Jennings, MS, RAC</i>	
Chapter 12	Combination Products	171
	<i>Updated by Allyson B. Mullen and Jeffrey N. Gibbs</i>	

Chapter 13	Global Regulatory Processes.....	183
	<i>Updated by Xianjun (Catherine) Chen, MS, RAC, Manuel Urena and Brian Young</i>	
Chapter 14	Global Regulatory Process—Third-Party Point of View	205
	<i>Updated by Gert Bos, MSc, PhD, FRAPS</i>	
Chapter 15	Use of Standards in Medical Device Global Regulatory Strategy.....	217
	<i>Updated by Susumu Nozawa, RAC, FRAPS</i>	
Chapter 16	Global Medical Device Marketing Strategy.....	241
	<i>Updated by Charles Tam, MBA</i>	
Chapter 17	Regulatory Resources for Strategy Development.....	259
	<i>Updated by Gretchen E. Parker, PhD, RAC, CIP</i>	
Chapter 18	Global Postmarketing Regulatory Strategy	287
	<i>Updated by Scott D. Dickerhoff</i>	
Chapter 19	Borderline Regulation of Stem Cell Technologies: Therapies, Devices and Combination Products	305
	<i>Updated by Anu Gaur, PhD, MBA, MSRA, RAC</i>	
Chapter 20	Patents and Intellectual Property.....	321
	<i>Updated by Stanley F. Chalvire, Sean D. Detweiler, David A. Fazzolare and Lisa M. Warren</i>	
Chapter 21	Software	335
	<i>Updated by Koen Cobbaert, MSEE, MSRM</i>	
Chapter 22	Cybersecurity	361
	<i>Updated by Colin Morgan, CISSP, CISM, GPEN</i>	
Glossary	373
Index	389

Figures

Figure 1-1.	Reimbursement for Medical Devices.....	7
Figure 4-1.	Comparison of Target Market Release Timelines	56
Figure 5-1.	Basic Process Model.....	61
Figure 5-2.	PDCA Cycle in Resource Management	62
Figure 5-3.	Mandatory Procedures and Documents for ISO 13485:2003	69
Figure 5-4.	Implementing an ISO 13485:2016 QMS	71
Figure 5-5.	Sample Schedule for QMS Implementation	73
Figure 5-6.	QMS Documentation Defining Responsibilities.....	74
Figure 5-7.	Typical QMS Document Hierarchy	75
Figure 5-8.	Iterative PDCA Cycle	77
Figure 5-9.	ISO 17021 QMS Certification Cycle.....	79

Figure 5-10.	Design Process	85
Figure 6-1.	FDA's View on Managing Pre- and Postmarket Product Risks	101
Figure 6-2.	FDA's Role in Medical Product Risk Management (Rx Products)	102
Figure 6-3.	Framework for Environmental Health Risk Management	103
Figure 7-1.	Example of Label Incorporating a UDI	114
Figure 7-2.	Example of a Medical Device Label for Use in Multiple Regions.....	115
Figure 9-1.	Strategy for Performing Animal Studies	143
Figure 13-1.	Regulatory Submission Process Flow.....	183
Figure 13-2.	Data Integrity Verification Process Outline.....	189
Figure 15-1.	Document Hierarchy	223
Figure 16-1.	Estimated Cost of Medical Device Regulatory Approval by Country	247
Figure 21-1.	Details of Scrum Methodology	347
Figure 22-1.	Product Security Framework From the JSP	363
Figure 22-2.	AAMI TIR57 and ISO14971 Crosswalk.....	366

Tables

Table 1-1.	Main Types of US Reimbursement Coding Systems	9
Table 1-2.	Types of Economic Evaluations	11
Table 3-1.	Example—Development Phases	25
Table 3-2.	Regulatory Pathway Assessment Elements.....	28
Table 3-3.	Regulatory Strategy and Plan Elements	37
Table 3-4.	Ebb and Flow of Core Team Member Involvement	43
Table 4-1.	Simplified Global Regulatory Strategy Element Table.....	48
Table 4-2.	Simplified Example of the Expanded Element Table	54
Table 4-3.	Regulatory Submission Requirements	55
Table 4-4.	Summary of Regulatory Risks	57
Table 5-1.	Key Differences Between ISO 9001 and ISO 13485.....	59
Table 5-2.	Similarities Between ISO 9001 and ISO 13485.....	60
Table 5-3.	Comparison of ISO 13485:2003 and ISO 13485:2016	64
Table 5-4.	Applicability of ISO 13485 in Various Global Jurisdictions.....	70
Table 5-5.	Benefits and Barriers to Certification	78
Table 5-6.	Certification Body QMS Assessment Objectives, Scope and Criteria	80
Table 5-7.	Audit Duration for Medical Device ISO 13485 Audits Based on Staff Numbers ...	80
Table 5-8.	Factors That May Increase or Reduce Audit Durations.....	81
Table 6-1.	Risk Mitigation Strategies	95
Table 7-1.	Key Medical Device Labeling Regulations in the EU MDR.....	112
Table 7-2.	Key Medical Device Labeling Regulations in the US: Code of Federal Regulation	113
Table 7-3.	ISO FDIS 20417: Medical Devices—Information to be Supplied by the Manufacturer	116
Table 9-1.	The Universal Elements of GLP	137
Table 9-2.	Examples of GLP Violations From FDA Warning Letters	138
Table 9-3.	Sources of Device Risk.....	139
Table 9-4.	Biocompatibility Tests.....	140
Table 9-5.	Medical Device Classification Based on the Nature of Body Contact and Contact Duration.....	141
Table 9-6.	Basic Animal Study Protocol Elements	142
Table 9-7.	Animal Models for In Vivo Medical Device Assessment.....	144

Table 9-8.	International Animal Research Laws, Policies and Guidelines.....	144
Table 9-9.	Useful Web Resources for Planning and Conducting Animal Studies in Accordance With the Three Rs' Principles	145
Table 9-10.	Questions a Company Should Consider When Selecting a CRO.....	146
Table 13-1.	Global Submission Planning and Prioritization Process	187
Table 13-2.	Considerations for Selecting In-Country Agents	199
Table 16-1.	Example of a CV Medical Device Company Product Development Matrix	242
Table 16-2.	Country-Specific Information from the Handbook of Pharma and MedTech Compliance.....	249
Table 16-3.	High-Level Marketing and Advertising Information for Countries in Asia-Pacific.....	250
Table 16-4.	High-Level Marketing and Advertising Information for Countries in Europe.....	251
Table 16-5.	High-Level Marketing and Advertising Information for Countries in Latin America and South America	252
Table 17-1.	African and Middle Eastern Regulatory Agencies	264
Table 17-2.	Asia/Pacific Regulatory Agencies	266
Table 17-3.	European Commission Competent Authorities	268
Table 17-4.	Eastern European Agencies	270
Table 17-5.	Latin American Regulatory Agencies.....	272
Table 17-6.	North American Regulatory Agencies.....	273
Table 17-7.	Global Regulatory Professional Trade Organizations	274
Table 17-8.	Miscellaneous Resources	278
Table 17-9.	African/Middle Eastern Intelligence Resources	280
Table 17-10.	Asia/Pacific Intelligence Resources	280
Table 17-11.	European Commission Intelligence Resources.....	281
Table 17-12.	Latin American Intelligence Resources	282
Table 17-13.	North American and Other Critical Intelligence Resources	283
Table 19-1.	Summary of Select Revenue-Generating Cell Therapy Products Currently on the Market	306
Table 19-2.	Definitions of Manipulations Considered Minimal (US) or Not Substantial (EU)	307
Table 19-3.	Summary of Regulatory Routes and Documents Applicable to Stem Cell and/or Device Products	309

1

Driving Successful Commercial Product Launches

Updated by Michael Reiner, MBA

Introduction

Healthcare is undergoing a radical transformation that is driven by uncontrollable cost increases, higher healthcare needs, increased regulatory scrutiny, as well as a shift in payment systems from a volume of care to value of care. New payment models that shift financial risk from payers to providers are evolving. To succeed in this environment, healthcare providers are focused more than ever on controlling the cost of care, being more efficient and delivering improved patient care. As these shifts in the healthcare system continue, new payment methodologies will continue to evolve that place greater emphasis and rewards on improved patient outcomes and provider efficiencies. A stakeholder's willingness to pay for a medical device will be tied to its impact on patient outcomes, cost-effectiveness and support for quality-based performance metrics.

To thrive and provide commercially ready products in this new environment, medical device manufacturers need to implement a collaborative and comprehensive approach in their product development process (PDP), with customer adoption as the goal. To achieve this result, medical device manufacturers will need to understand and demonstrate how their product improves patient outcomes while increasing efficiencies and value to multiple stakeholders within the healthcare delivery system.

This chapter will provide the reader, especially those responsible for developing and building a regulatory strategy, with a framework to achieve a successful commercial product launch. Regulatory leaders and leaders from other cross-functional departments must

recognize that their strategies and tactics should not be viewed from their perspective alone. Instead, they must understand that they are part of a process that has a patient-centered and market adoption end in mind. To thrive in this evolving healthcare environment, a collaborative cross-functional market access approach must be embraced by everyone in the organization.

Commercialization Through Cross-Functional Collaboration with Market Access Mindset

In the past, most medical device manufacturers rarely considered payment, value or the end user of their products in their PDP, or may have only considered some of these at the time of product launch. As medical device manufacturers recognize the complexities of the new marketplace, they also have discovered this previous approach has led to poor commercial results. Increasingly, medical device manufacturers are integrating payment, value and other patient- and customer-focused criteria in their strategies very early in the process. Marketplace adoption of medical devices is increasingly dependent upon a range of stakeholders beyond the physician. These stakeholders include payers, patients, regulators, government policy makers and multiple clinical and economic decision makers within healthcare provider systems. Each of these stakeholders brings a unique set of perspectives on how they expect a medical device to impact quality and cost of care. A medical device manufacturer will need to understand each of these stakeholder perspectives and demonstrate how their device meets the demands of improved quality, lower

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22